Skip to main content

Advertisement

Log in

Vision-related quality-of-life in pediatric primary brain tumor patients

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

Brain tumors are the leading cause of death from childhood cancer. Although overall survival has improved due to earlier detection, better therapies, and improved surveillance, visual dysfunction and impaired vision-related quality-of-life (VR-QOL) are often unrecognized in children. This project investigated VR-QOL in pediatric brain tumor patients.

Methods

We evaluated visual impairment and quality-of-life (QOL) in a quality improvement project at one tertiary care center. Patients ≤ 18, greater than 6 months from diagnosis of brain tumor, excluding intrinsic anterior visual pathway tumors, underwent standardized neuro-ophthalmologic examination. Health-related QOL (HR-QOL) (PedsQL Brain Tumor Module) and VR-QOL questionnaires [CVFQ (Children’s Visual Function Questionnaire) in children < 8, and EYE-Q in children 8–18] were obtained from patients and parents.

Results

Among 77 patients, craniopharyngiomas (n = 16, 21%) and astrocytomas (n = 15, 20%) were the most common tumors. Among 44/77 (57%) visually impaired children, 7 (16%) were legally blind. Eye-Q median score was 3.40 (interquartile range 3.00–3.75), worse than average scores for normal children. Eye-Q score decreased 0.12 with every 0.1 increase in logMAR visual acuity (p < 0.001). Patients who were legally blind had a significantly lower Eye-Q score than those who were not [0.70 vs. 3.44 (p < 0.001)]. Cognitive HR-QOL scores decreased 1.3 for every 0.1 increase in logMAR visual acuity (p = 0.02).

Conclusions

Pediatric brain tumor patients’ vision, HR-QOL, and VR-QOL were often severely affected even when tumors were considered cured. Visual acuity and legal blindness correlated with VR-QOL. Systematic neuro-ophthalmologic examinations in pediatric primary brain tumor patients are necessary to facilitate early preventative and corrective ophthalmologic interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets generated during and/or analysed during the current project are available from the corresponding author on reasonable request.

References

  1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-oncol 22(S1):iv1-v96. https://doi.org/10.1093/neuonc/noaa200

  2. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975–2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021. Accessed 25 June 2021

  3. Pollack IF (2009) Diagnosis and treatment of childhood brain tumors: Current perspectives. J Child Neurol 24:1464–1465. https://doi.org/10.1177/0883073809338961

    Article  PubMed  Google Scholar 

  4. Jariyakosol S, Peragallo JH (2015) The effects of primay brain tumors on vision and quality of life in pediatric patients. Semin Neurol 35:587–598. https://doi.org/10.1353/nib.2014.0006

    Article  PubMed  Google Scholar 

  5. Liu Y, Abongwa C, Ashwal S, Deming DD, Winter TW (2019) Referral for ophthalmology evaluation and visual sequelae in children with primary brain tumors. JAMA Netw Open 2(8):e198273. https://doi.org/10.1001/jamanetworkopen.2019.8273

    Article  PubMed  PubMed Central  Google Scholar 

  6. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA (2017) Optic pathway gliomas in neurofibromatosis type 1: An update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol 37(Suppl 1):S23–S32. https://doi.org/10.1097/wno.0000000000000550

    Article  PubMed  PubMed Central  Google Scholar 

  7. Møller HU, Larsen DA (2017) Milestones and normative data. In: Lambert SR, Lyons CJ (eds) Taylor and Hoyt’s pediatric ophthalmology and strabismus, 5th edn. Elsevier, Edinburgh, pp 40–49

    Google Scholar 

  8. Palmer SN, Meeske KA, Katz ER, Burwinkle TM, Varni JW (2007) The PedsQL brain tumor module: initial reliability and validity. Pediatr Blood Cancer 49(3):287–293. https://doi.org/10.1002/pbc.21026

    Article  PubMed  Google Scholar 

  9. Felius J, Stager DR Sr, Berry PM, Fawcett SL, Stager DR Jr, Salomão SR, Berezovsky A, Birch EE (2004) Development of an instrument to assess vision-related quality of life in young children. Am J Ophthalmol 138(3):362–372. https://doi.org/10.1016/j.ajo.2004.05.010

    Article  PubMed  Google Scholar 

  10. Birch EE, Cheng CS, Felius J (2007) Validity and reliability of the Children’s Visual Function Questionnaire (CVFQ). J AAPOS 11(5):473–479. https://doi.org/10.1016/j.jaapos.2007.02.011

    Article  PubMed  PubMed Central  Google Scholar 

  11. Angeles-Han ST, Griffin KW, Harrison MJ, Lehman TJA, Leong T, Robb RR, Shainberg M, Ponder L, Lenhart P, Hutchinson A, Srivastava SK, Prahalad S, Lambert SR, Drews-Botsch C (2011) Development of a vision-related quality of life instrument for children ages 8–18 years for use in juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken) 63(9):1254–1261. https://doi.org/10.1002/acr.20524

    Article  Google Scholar 

  12. Gadgil N, Edmond J, Stormes K, Lam S, Shah V (2019) Visual complications of pediatric posterior fossa tumors: analysis of outcomes. Pediatr Neurol 92:48–54. https://doi.org/10.1016/j.pediatrneurol.2018.09.016

    Article  PubMed  Google Scholar 

  13. Wan MJ, Zapotocky M, Bouffet E, Bartels U, Kulkarni AV, Drake JM (2018) Long-term visual outcomes of craniopharyngioma in children. J Neurooncol 137(3):645–651. https://doi.org/10.1007/s11060-018-2762-3

    Article  PubMed  Google Scholar 

  14. Peeler CE, Edmond JC, Hollander J, Alexander JK, Zurakowski D, Ullrich NJ, Manley PE, Heidary G (2017) Visual and ocular motor outcomes in children with posterior fossa tumors. J AAPOS 21(5):375–379. https://doi.org/10.1016/j.jaapos.2017.05.032

    Article  PubMed  Google Scholar 

  15. Bialer OY, Goldenberg-Cohen N, Toledano H, Snir M, Michowiz S (2013) Retinal NFL thinning on OCT correlates with visual field loss in pediatric craniopharyngioma. Can J Ophthalmol 48:494–499. https://doi.org/10.1016/j.jcjo.2013.05.001

    Article  PubMed  Google Scholar 

  16. Bhat SR, Goodwin TL, Burwinkle TM, Lansdale MF, Dahl GV, Huhn SL, Gibbs IC, Donaldson SS, Rosenblum RK, Varni JW, Fisher PG (2005) Profile of daily life in children with brain tumors: an assessment of health-related quality of life. J Clin Oncol 23(24):5493–5500. https://doi.org/10.1200/jco.2005.10.190

    Article  PubMed  Google Scholar 

  17. Liu GT, Galetta SL (1997) Homonymous hemifield loss in childhood. Neurology 49(6):1748–1749. https://doi.org/10.1212/wnl.49.6.1748

    Article  CAS  PubMed  Google Scholar 

  18. Kedar S, Zhang X, Lynn MJ, Newman NJ, Biousse V (2006) Pediatric homonymous hemianopia. J AAPOS 10(3):249–252. https://doi.org/10.1016/j.jaapos.2006.01.181

    Article  PubMed  Google Scholar 

  19. Harbert MJ, Yeh-Nayre LA, O’Halloran HS, Levy ML, Crawford JR (2012) Unrecognized visual field deficits in children with primary central nervous system brain tumors. J Neurooncol 107:545–549. https://doi.org/10.1007/s11060-011-0774-3

    Article  CAS  PubMed  Google Scholar 

  20. Peragallo JH (2018) Effects of brain tumors on vision in children. Int Ophthalmol Clin 58(4):83–95. https://doi.org/10.1097/iio.0000000000000237

    Article  PubMed  PubMed Central  Google Scholar 

  21. Lanphear J, Sarnaik S (2014) Presenting symptoms of pediatric brain tumors diagnosed in the emergency department. Pediatr Emerg Care 30(2):77–80. https://doi.org/10.1097/pec.0000000000000074

    Article  PubMed  Google Scholar 

  22. Chadha RK, Subramanian A (2011) The effect of visual impairment on quality of life of children aged 3–16 years. Br J Ophthalmol 95(5):642–645. https://doi.org/10.1136/bjo.2010.182386

    Article  PubMed  Google Scholar 

  23. Boulton M, Haines L, Smyth D, Fielder A (2006) Health-related quality of life in children with vision impairment or blindness. Dev Med Child Neurol 48(8):656–661. https://doi.org/10.1017/s0012162206001381

    Article  PubMed  Google Scholar 

  24. Avery RA, Hardy KK (2014) Vision specific quality of life in children with optic pathway gliomas. J Neurooncol 116:341–347. https://doi.org/10.1007/s11060-013-1300-6

    Article  PubMed  Google Scholar 

  25. Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT, REiNS International Collaboration (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81(21, Suppl 1):S15-S24. https://doi.org/10.1212/01.wnl.0000435745.95155.b8

  26. Leske DA, Hatt SR, Castañeda YS, Wernimont SM, Liebermann L, Cheng-Patel CS, Birch EE, Holmes JM (2019) Validation of the pediatric eye questionnaire in children with visual impairment. Am J Ophthalmol 208:124–132. https://doi.org/10.1016/j.ajo.2019.07.018

    Article  PubMed  PubMed Central  Google Scholar 

  27. Okamoto Y, Okamoto F, Hiraoka T, Yamada S, Oshika T (2008) Vision-related quality of life in patients with pituitary adenoma. Am J Ophthalmol 146(2):318–322. https://doi.org/10.1016/j.ajo.2008.04.018

    Article  PubMed  Google Scholar 

  28. Okamoto Y, Okamoto F, Yamada S, Honda M, Hiraoka T, Oshika T (2010) Vision-related quality of life after transsphenoidal surgery for pituitary adenoma. Invest Ophthalmol Vis Sci 51(7):3405–3410. https://doi.org/10.1167/iovs.09-3763

    Article  PubMed  Google Scholar 

Download references

Funding

This research was supported in part by a grant from the Knights Templar of the state of Georgia. Dr Bruce was a data and scientific monitoring committee member for VielaBio and a medicolegal consultant for Bayer and for individual litigants on the topic of idiopathic intracranial hypertension. Dr Biousse and Dr Newman are consultants for GenSight Biologics and Neurophoenix. Dr Newman is a consultant for Santhera Pharmaceuticals and Stealth BioTherapeutics. Dr Biousse and Dr Newman are supported by the National Institutes of Health’s National Institute of Neurological Diseases and Stroke (R01-NSO89694). Dr Peragallo, Dr Biousse and Dr Newman are supported in part by the National Institutes of Health’s National Eye Institute core grant P30-EY06360 (Department of Ophthalmology, Emory University School of Medicine).

Author information

Authors and Affiliations

Authors

Contributions

Experimental design: JP, BB, SJ, AJ, NN, VB. Design implementation: JP, BB, CV, SJ, NN, VB. Analysis or interpretations of data: JP, BB, CV, NN, VB. Involved in writing the draft of, revising, reading, and approving the final manuscript: All authors.

Corresponding author

Correspondence to Jason H. Peragallo.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest.

Ethical approval

Exempt from formal review per institutional review board.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendix 1: Additional questions asked of participants and their parents

Appendix 1: Additional questions asked of participants and their parents

  1. (1)

    Do you require special assistance at school, such as an independent education plan (IEP) or 504 plan?

  2. (2)

    Do you wear glasses? Do you require additional low vision assistance, such as brail, a cane, or magnifier? If so, please specify.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Peragallo, J.H., Bruce, B.B., Vasseneix, C. et al. Vision-related quality-of-life in pediatric primary brain tumor patients. J Neurooncol 154, 365–373 (2021). https://doi.org/10.1007/s11060-021-03835-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-021-03835-2

Keywords

Navigation